Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFKB1 | P19838 | 4/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 4/20 | 0.41 |
| ▸ | RELA | Q04206 | 4/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | BTK | Q06187 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 2/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6283768 | 0.89 | NFKB1 (0.38) | NFKB1NFKB2RELAKMT2AALDH1A1 | |
| SCHEMBL6285830 | 0.81 | NAAA (0.36) | NFKB1NFKB2RELAKMT2AALDH1A1 | |
| SCHEMBL6286420 | 0.75 | NFKB1 (0.45) | NFKB1NFKB2RELAKMT2AALDH1A1 | |
| SCHEMBL25608427 | 0.72 | NFKB1 (0.50) | NFKB1NFKB2RELAKMT2AL3MBTL1 | |
| SCHEMBL4586907 | 0.71 | NFKB1 (0.41) | NFKB1NFKB2RELAKMT2AALDH1A1 | |
| SCHEMBL4585524 | 0.71 | NFKB1 (0.46) | NFKB1NFKB2RELAKMT2AALDH1A1 | |
| SCHEMBL4586708 | 0.70 | NFKB1 (0.40) | NFKB1NFKB2RELAKMT2AALDH1A1 | |
| SCHEMBL10413343 | 0.69 | NFKB1 (0.49) | NFKB1NFKB2RELAKMT2AALDH1A1 | |
| SCHEMBL17467742 | 0.69 | NFKB1 (0.49) | NFKB1NFKB2RELAKMT2AALDH1A1 | |
| SCHEMBL17467814 | 0.68 | NFKB1 (0.48) | NFKB1NFKB2RELAKMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6962907-B2 | Neurologically-active compounds | THE UNIVERSITY OF SYDNEY (AU) | 2005-11-08 | — | — | US | disclosed |
| US-20050004083-A1 | Neurologically-active compounds | NEURO THERAPEUTICS LIMITED (AU) | 2005-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004083-A1 | Neurologically-active compounds | GABRA2, GABRA5, GABRE | NFKB1 483/4885NFKB2 503/4885RELA 994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.